事業提携・ライセンシング・投資・M&A動向(四半期別):Q3 2013...市場調査レポートについてご紹介

【英文タイトル】Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2013 25
3.1.1 Top M&A Deals in Q3 2013 26
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2012 – Q3 2013 27
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 – Q3 2013 33
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 – Q3 2013 39
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2012 – Q3 2013 43
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 – Q3 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 – Q3 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 – Q3 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 – Q3 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 – Q3 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 – Q3 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 – Q3 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 – Q3 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 – Q3 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 – Q3 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 – Q3 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 – Q3 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 – Q3 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 – Q3 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 – Q3 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System – Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease – Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology – Deals of the Quarter 107
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders – Deals of the Quarter 110
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular – Deals of the Quarter 114
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal – Deals of the Quarter 118
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology – Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory – Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology – Deals of the Quarter 128
8 Deal Summary by Geography 130
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America – Deals of the Quarter 132
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe – Deals of the Quarter 137
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific – Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World – Deals of the Quarter 146
9 Pharmaceuticals & Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 148
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150
10 Appendix 152
11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158


【レポート販売概要】

■ タイトル:事業提携・ライセンシング・投資・M&A動向(四半期別):Q3 2013
■ 英文:Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
■ 発行日:2013年11月30日
■ 調査会社:GlobalData
■ 商品コード:GDATA403162973
■ 調査対象地域:グローバル
  • 世界のコントロールバルブ市場動向(2012-2016)
    TechNavio's analysts forecast the Global Control Valve market to grow at a CAGR of 5.86 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand for control valves from developing countries. The Global Control Valve Market has also been witnessing an increase in the development and adoption of smart control valves. However, the rise in the …
  • 建設機械の世界市場:土工機械、マテリアルハンドリング機械、コンクリート/道路建設機械
    About Construction Equipment Construction equipment is used to perform multiple tasks on the construction site such as hoisting, excavating, hauling, paving, grading, and drilling. Construction equipment has many uses in the building and realty sector. This type of equipment includes excavators, loaders, construction tractors, graders, rollers, scrapers, conveyors, cranes, compactors, and pavers. …
  • 自動車用パワースライドドアシステムの世界市場2018-2022
    About Automotive Power Sliding Door System An automotive door is typically hinged, but in many cases, it can also be attached by other mechanisms, such as tracks. The doors in a vehicle can either be opened manually or can be powered electronically. Technavio’s analysts forecast the global automotive power sliding door system market to grow at a CAGR of 18.31% during the period 2018-2022. Covered …
  • Cepheid:市場シェア分析
    Cepheid Market Share Analysis Summary GlobalData’s new report, “Cepheid Market Share Analysis” provides in-depth information on Cepheid’s market position in the different medical equipment markets it operates in. The report provides Cepheid market share information in two key market categories – Genetic Testing and Infectious Immunology. The report also provides data and information on the overall …
  • 写真商品の世界市場2016-2020
    About Photo MerchandisingPhoto merchandise refers to personalized gifting and décor products that use photographs. These products are mainly used by corporate and individual customers that wish to offer customized gifts. Photo cards and calendars are examples of photo merchandise products. Technavio’s analysts forecast the global photo merchandising market to grow at a CAGR of 9.69% during the per …
  • 世界のメチルエチルケトン(MEK)市場2015
    The Global Methyl Ethyl Ketone (MEK) Industry Report 2015 is a professional and in-depth study on the current state of the Methyl Ethyl Ketone (MEK) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Methyl Ethyl Ketone (MEK) market analysis is provided for the international markets including developm …
  • 世界のコンピュータグラフィックス(CG)市場(2014-2019)
    Computer graphics industry as being a part of designing industries is categorized by creativity and innovation skill set. Computer graphics software are now widely being adopted across many industries, such as media and entertainment, advertising and television industry, computer gaming, corporate and commercial production, digital photo and video, and publishing. Computer graphics recently achiev …
  • 発電業界のM&A及び投資動向(四半期別):Q2 2013
    Power Quarterly Deals Analysis: M&A and Investment Trends - Q2 2013 Summary GlobalData’s “Power Quarterly Deals Analysis: M&A and Investment Trends - Q2 2013” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), venture finan …
  • 2014 Leading Flavor and Fragrances Market Players: Firmenich, Frutarom, Givaudan, T. Hasegawa, IFF, Mane, Robertet, Sensient, Symrise, Takasago
    The companies analyzed in this report include Firmenich, Frutarom, Givaudan, T. Hasegawa, IFF, Mane, Robertet, Sensient, Symrise, and Takasago.  The report presents:Business goals and strategies, including internal expansion, acquisitions, and divestitures.Specific business, new product development and marketing objectives and strategies.Major strengths and weaknesses.Anticipated acquisitions …
  • グローバル香料市場におけるM&A動向(2014年3月)
    Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global fragrances market during March 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global fragrances market throughout the month. Additionally, the report provides an overview of all the part …
  • Venous Thromboembolism:グローバル臨床試験レビューH1, 2013
    Venous Thromboembolism Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Venous Thromboembolism Global Clinical Trials Review, H1, 2013" provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism . It includes an overview of the trial numbers an …
  • LEDグローライトの世界市場
    Light-Emitting Diode (LED) grow light is a specialized kind of LED lighting system, which is witnessing increased adoption across all application areas. This is primarily due to the capacity of this technology to produce food in controlled environment through vertical farming, commercial greenhouse, and indoor farming among many others. The increasing population in urban areas requires high food p …
  • 有機ライスタンパク質の世界市場分析:製品別(ライスタンパク質分離物、ライスタンパク質濃縮物)、用途別(スポーツ・エネルギー栄養学、製パン・製菓、肉類代用品・増量剤、乳製品代替品)、セグメント予測
    The global organic rice protein market is expected to reach USD 154.4 million by 2024, according to a new report by Grand View Research, Inc. Superior functional properties coupled with increasing shift towards non-GMO and vegan food ingredients is expected to propel the demand over the forecast period. The product is hypoallergenic and generally consists of no added colors, sweeteners or fillers …
  • 補助人工心臓の世界市場:左室補助人工心臓(LVAD)、右室補助人工心臓(RVAD)、両心補助人工心臓(BiVAD)
    About Ventricular Assist Devices Heart failure is a medical condition wherein the heart loses its ability to pump enough blood to circulate throughout the body. In such a condition, a patient can survive by having heart transplantation with a healthy heart. A VAD is a medical device that is used to support the patient with either acute or chronic cardiac functional deterioration. It is a mechanica …
  • アジア太平洋の衛星ベースEO(地球観測)市場2016-2020
    About the Satellite-Based Earth Observation (EO) Market in APAC Earth observation is the collection of necessary information and data about Earth through remote sensing technologies like specially designed satellites. The data from these satellites are intended for use in various application sectors like environmental monitoring, agriculture, water resources, urban planning, rural development, for …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。